Stephens Lowers OraSure Technologies (NASDAQ:OSUR) Price Target to $3.00

OraSure Technologies (NASDAQ:OSUR) had its price target decreased by stock analysts at Stephens from $3.50 to $3.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has an “equal weight” rating on the medical instruments supplier’s stock. Stephens’ price target would suggest a potential upside of 31.58% from the stock’s current price.

Separately, Weiss Ratings reissued a “sell (d)” rating on shares of OraSure Technologies in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, OraSure Technologies presently has a consensus rating of “Reduce” and a consensus target price of $3.00.

OraSure Technologies Stock Down 7.7%

Shares of NASDAQ OSUR opened at $2.28 on Wednesday. The business’s 50 day moving average price is $3.00 and its 200 day moving average price is $2.97. The firm has a market cap of $163.55 million, a P/E ratio of -3.40 and a beta of 0.54. OraSure Technologies has a 52 week low of $2.27 and a 52 week high of $4.22.

OraSure Technologies (NASDAQ:OSUR) last posted its quarterly earnings results on Wednesday, November 5th. The medical instruments supplier reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03. OraSure Technologies had a negative net margin of 36.84% and a negative return on equity of 10.81%. The company had revenue of $27.09 million during the quarter, compared to analyst estimates of $28.96 million. OraSure Technologies has set its Q4 2025 guidance at EPS. As a group, research analysts expect that OraSure Technologies will post -0.08 earnings per share for the current year.

Institutional Investors Weigh In On OraSure Technologies

Institutional investors have recently modified their holdings of the business. Sei Investments Co. increased its stake in shares of OraSure Technologies by 16.4% in the 3rd quarter. Sei Investments Co. now owns 32,244 shares of the medical instruments supplier’s stock valued at $103,000 after purchasing an additional 4,536 shares in the last quarter. UBS Group AG grew its holdings in OraSure Technologies by 98.2% in the third quarter. UBS Group AG now owns 722,520 shares of the medical instruments supplier’s stock valued at $2,319,000 after purchasing an additional 358,016 shares during the period. BNP Paribas Financial Markets increased its position in shares of OraSure Technologies by 102.2% in the third quarter. BNP Paribas Financial Markets now owns 15,275 shares of the medical instruments supplier’s stock valued at $49,000 after buying an additional 7,720 shares in the last quarter. Russell Investments Group Ltd. raised its stake in shares of OraSure Technologies by 30.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 38,498 shares of the medical instruments supplier’s stock worth $124,000 after buying an additional 9,012 shares during the period. Finally, Private Advisor Group LLC purchased a new position in shares of OraSure Technologies during the 3rd quarter valued at approximately $57,000. 93.50% of the stock is currently owned by institutional investors and hedge funds.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.